Baltimore, Maryland, – Rapid®, in collaboration with Dr. Wesley Bolch and his group at the University of Florida, have been awarded a $1.65 million NCI Phase II SBIR grant to advance its innovative dosimetry calculation software, 3D-RD-S, by integrating crucial features for α-emitter radiopharmaceutical therapy (α-RPT). This funding will accelerate the development of a cutting-edge dosimetry tool designed to improve treatment planning and safety for cancer patients undergoing α-RPT.
Radiopharmaceutical therapy (RPT) leverages targeted radionuclides to deliver radiation directly to cancer cells. While the field rapidly expands, current dosimetry tools are primarily designed for diagnostic imaging or beta-emitter therapies and lack the capabilities needed for α-RPT applications. The newly funded project aims to address this gap by incorporating unique features that enable precise dose calculations for α-particles, which are known for their high potency and short range.
The project will build upon Rapid’s existing 3D-RD-S platform, a cloud-based dosimetry tool that adheres to Medical Internal Radiation Dose (MIRD) Committee standards. Key advancements funded by this grant include the development of a library of microscale S-values for critical tissues, implementation of the innovative macro-to-micro (M2μ) methodology for accurate dosimetry, and integration of user-friendly educational materials
to support clinicians and regulatory authorities.
“This grant is a significant milestone for Rapid and our ongoing mission to advance radiopharmaceutical dosimetry,” said Dr. George Sgouros, Co-Founder of Rapid and Professor of Radiology at Johns Hopkins University. “By enhancing our 3D-RD-S platform with these essential α-RPT features, we aim to provide clinicians with the tools they need to deliver safe and effective cancer treatments.”
The integration of the M2μ methodology, initially developed at Johns Hopkins, will enable clinicians to assess normal tissue toxicity more accurately. This is a critical consideration in α-RPT, where traditional imaging techniques fall short. The expanded capabilities of 3D-RD-S will support more personalized and effective treatment planning, ultimately improving patient outcomes.
Rapid is committed to setting new standards in the field of radiopharmaceutical dosimetry, and this NCI grant represents a pivotal step forward in making advanced cancer therapies more accessible and effective.
Contact:
Denis Sgouros
Marketing & Sales, Rapid
Email: dsgouros@rapiddosimetry.com
About Rapid
Rapid is a leader in quantitative imaging and dosimetry solutions, providing innovative software and expert services to support the development and clinical implementation of radiopharmaceutical therapies. Founded by a team of industry experts, Rapid is dedicated to advancing the standards of dosimetry in cancer treatment.
